Epirium Bio

Epirium Bio, formerly known as Cardero Therapeutics, is a clinical-stage biopharmaceutical company developing therapeutics that promote mitochondrial biogenesis and function through a novel mechanism of action discovered by the company.

Epirium Bio is dedicated to developing life-saving therapies through unique scientific innovation.

Epirium Bio was founded in 2008 and is headquartered in San Diego, California.


Epirium Bio has developed unique insights related to the biology of mitochondrial biogenesis and tissue function, potentially resulting in novel therapeutic approaches to currently intractable neuromuscular diseases.


Epirium Bio has identified and established an IP-protected platform of small molecules that constitute a new class of therapeutics with the potential to stimulate mitochondrial biogenesis and tissue regeneration. Epirium is currently planning clinical trials with its initial drug candidate in Becker muscular dystrophy.


Epirium Bio is backed by Longitude Capital, ARCH Venture Partners, Bluebird Ventures, Adams Street Partners, Vertex Ventures HC, The Longevity Fund and others. The company raised $85M in a Series A financing on Dec 18, 2019. 



  • Year founded: 2008
  • Funding Info: $85M over 1 Round (Latest Funding Type: Series A)
  • Yearly Revenue: NA
  • Employee Size: 2-10
  • Business Valuation: NA
  • City/Town: San Diego
  • State: California
  • Country: United States
Related businesses